MICHELLE VASQUEZ: Open Payments
NPI 1942919022 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,642 in 34 payments from 19 companies in 2025. Trend: 2023 $652 · 2024 $690 · 2025 $1,642
Food & beverage: $1,642
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $260 |
| Novartis Pharmaceuticals Corporation | 10 | $241 |
| Legend Biotech USA Inc. | 1 | $149 |
| SANOFI-AVENTIS U.S. LLC | 1 | $125 |
| GlaxoSmithKline, LLC. | 1 | $125 |
| Janssen Biotech, Inc. | 1 | $125 |
| Kite Pharma, Inc. | 1 | $113 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $98 |
| SOBI, INC | 2 | $62 |
| Azurity Pharmaceuticals, Inc. | 2 | $61 |
Products named: CARVYKTI, Fabhalta, LYNPARZA, REZUROCK, JEMPERLI, DATROWAY, RYBREVANT, Yescarta.
Industry payments across NY — which companies pay providers there.
